The Veterinary Biologics Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size of the veterinary biologics sector has experienced significant growth in the past. It is projected to increase from $12.67 billion in 2024 to $13.65 billion in 2025, with a compound annual growth rate (CAGR) of 7.7%.
The Veterinary Biologics Global Market Report 2024 forecasts that by 2029, the market size will reach $18.38 billion, growing at a compound annual growth rate (CAGR) of 7.7%.
Download Your Free Sample of the 2025 Veterinary Biologics Market Report and Uncover Key Trends Now!The key drivers in the veterinary biologics market are:
• Emergence of new infectious diseases and change in disease patterns due to climate change
• Increased adoption of precision livestock farming techniques
• Rising acceptance of the "one health" approach which integrates animal, human, and environmental health
• Surge in pet ownership trends worldwide.
The veterinary biologics market covered in this report is segmented –
1) By Product: Vaccines, Diagnostic Kits, Immunomodulators, Antiserums And Antibodies, Other Products
2) By Disease Type: Bluetongue, Foot And Mouth Disease, Brucellosis And Tuberculosis, Other Diseases
3) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Other Distribution Channels
4) By Application: Production Animal, Companion Animal
The key trends in the veterinary biologics market are:
• The trend of education and training programs is emerging in the market.
• eco-friendly and sustainable biologics is a significant emerging trend.
• The veterinary biologics market will be influenced by the integration of digital health records.
• Increasing focus on companion animal biologics and customized, targeted therapies is another emerging trend.
The major players in the veterinary biologics market are:
• Bayer AG
• Eli Lilly & Company
• Evonik Industries AG
• Zoetis Inc
North America was the largest region in the veterinary biologics market in 2024